Results 31 to 40 of about 92,350 (272)

Tocilizumab Is Associated with Increased Risk of Fungal Infections among Critically Ill Patients with COVID-19 and Acute Renal Failure: An Observational Cohort Study

open access: yesLife, 2023
Research Question: Does treatment with tocilizumab increase the risk of a fungal infection in critically ill patients with coronavirus-19? Background: Numerous therapies have been evaluated as possible treatments for coronavirus-2019 caused by severe ...
Barrett J. Burger   +5 more
doaj   +1 more source

Efficacy of tocilizumab in the treatment of COVID‐19: An umbrella review

open access: yes, 2022
Tocilizumab is an interleukin (IL)‐6 receptor inhibitor that has been proposed as a therapeutic agent for treating coronavirus disease 2019 (COVID‐19). The aim of this umbrella review was to determine the efficacy of tocilizumab in treating COVID‐19, and
Rezaei Tolzali, Mohammad Mahdi   +25 more
core   +1 more source

Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review

open access: yesPediatric Rheumatology Online Journal, 2018
Tocilizumab, an anti-interleukin-6 (IL-6) agent, is indicated as a treatment for several autoimmune or inflammatory diseases, including rheumatoid arthritis and juvenile idiopathic arthritis (JIA). IL-6 plays roles in both immune system dysregulation and
Ju-Yang Jung   +3 more
doaj   +1 more source

Tocilizumab increases citrullinated histone 3 in non-ST segment elevation myocardial infarction

open access: yesOpen Heart, 2021
Objective Beyond reducing inflammation and troponin T (TnT) release, the interleukin-6 receptor antagonist tocilizumab reduces neutrophil counts in patients with non-ST segment elevation myocardial infarction (NSTEMI). It is unclear if this is related to
Thor Ueland   +10 more
doaj   +1 more source

Successful Use of Tocilizumab in a Patient with Coexisting Rheumatoid Arthritis and Ulcerative Colitis

open access: yesCase Reports in Immunology, 2016
Tocilizumab is an interleukin-6 receptor inhibitor licensed for moderate to severe rheumatoid arthritis (RA). We report a case of Tocilizumab monotherapy for severe active RA in a patient with coexisting ulcerative colitis (UC).
Matthew Chak Hin Szeto   +3 more
doaj   +1 more source

Cytokine pattern in patients with ST-elevation myocardial infarction treated with the interleukin-6 receptor antagonist tocilizumab

open access: yesOpen Heart, 2023
Background Tocilizumab improves myocardial salvage index (MSI) in patients with ST-elevation myocardial infarction (STEMI), but its mechanisms of action are unclear. Here, we explored how cytokines were affected by tocilizumab and their correlations with
Ola Kleveland   +19 more
doaj   +1 more source

Tocilizumab as a steroid sparing agent for the treatment of Graves' orbitopathy

open access: yesAmerican Journal of Ophthalmology Case Reports, 2017
Purpose: To describe the effect of tocilizumab in two patients with thyroid associated orbitopathy (TAO). Observations: We present two patients with TAO who could not tolerate corticosteroids and had a reduction in clinical and laboratory markers of ...
David J. Russell   +2 more
doaj   +1 more source

Comparison of the inhibitory effect of tocilizumab and etanercept on the progression of joint erosion in rheumatoid arthritis treatment

open access: yesScientific Reports, 2022
We compared the efficacy of tocilizumab and etanercept in inhibiting radiographic progression of joint destruction in rheumatoid arthritis. Overall, 187 patients treated with etanercept or tocilizumab were selected.
Shinya Hayashi   +11 more
doaj   +1 more source

Prevalence of adverse events post tocilizumab administration.

open access: yes, 2021
Prevalence of adverse events post tocilizumab administration.
Maryam Al-Melahi (11326697)   +6 more
core   +1 more source

Tocilizumab, recurso terapéutico de vanguardia contra la infección por SARS-CoV-2: una revisión exploratoria

open access: yes, 2023
OBJETIVO: Explorar la evidencia médica publicada hasta el 20 de abril de 2022 sobre la eficacia y seguridad de tocilizumab en pacientes con COVID-19.
Mora Karam, Claudia   +7 more
core   +1 more source

Home - About - Disclaimer - Privacy